NCT00744939 - Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

November 30, 2013

Conditions

FibrosisKidney FailureRenal Insufficiency

Interventions

DRUG

Gadopentetate dimeglumine (Magnevist, BAY86-4882)

Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop

Trial Locations (26)

10016

New York

11219

Brooklyn

11790

Stony Brook

19104

Philadelphia

19141

Philadelphia

21287

Baltimore

22908

Charlottesville

38104

Memphis

44195

Cleveland

66604

Topeka

77030

Houston

78229

San Antonio

81008

Pueblo

85008

Phoenix

90033

Los Angeles

91910

Chula Vista

95405

Santa Rosa

96813

Honolulu

96859

Honolulu

98321

Tacoma

06520--804

New Haven

32209-6595

Jacksonville

02114

Boston

02118

Boston

02215

Boston

17822-2001

Danville